Fluorescence Cystoscopy in Bladder Cancer: The Case Pro

European Urology, Supplements

Volumn 7, Issue 5, 2008, Pages 426-429

  Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Diagnosis; Fluorescence cystoscopy

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER;

BLADDER CANCER; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA IN SITU; COST OF ILLNESS; CYSTOSCOPY; DIAGNOSTIC PROCEDURE; FLUORESCENCE; FLUORESCENCE CYSTOSCOPY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SAFETY; TRANSURETHRAL RESECTION;

EID: 44549088673     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.12.007     Document Type: Review

References (20)

1. Sylvester R., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
2. Botteman M., Pashos C., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
3. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
4. Babjuk M., Soukup V., Petrik R., Jirsa M., and Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 96 (2005) 798-802
5. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 170 (2003) 226-229
6. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., and Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate (HAL) fluorescence cystoscopy. J Urol 171 (2004) 135-138
7. Krieg R., Messmann H., Rauch J., Seeger S., and Knuechel R. Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem Photobiol 76 (2002) 518-525
8. Witjes J.A., and Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 4 (2007) 542-549
9. Marti A., Lange N., van den Bergh H., Sedmera D., Jichlinski P., and Kucera P. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol 162 (1999) 546-552
10. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using Hexvix imaging: a prospective phase III multi-centre study. J Urol 174 (2005) 862-866
11. Fradet Y., Grossman H.B., Gomella L., et al. A comparison of hexaminolevulinate (HAL) fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ (CIS) in patients with bladder cancer: a phase III, multicenter study. J Urol 178 (2007) 68-73
12. Grossman H.B., Gomella L., Fradet Y., et al. A phase III, multicenter comparison of hexaminolevulinate (HAL) fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178 (2007) 62-67
13. Witjes J., Moonen P.M.J., and van der Heijden A.G. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 47 (2005) 319-322
14. Loidl W., Schmidbauer J., Susani M., and Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?. Eur Urol 47 (2005) 323-326
15. Filbeck T., Roessler W., Knuechel R., Straub M., Kiel H.J., and Wieland W.F. Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 13 (1999) 117-121
16. Grimbergen M.C.M., van Swol C.F.P., Jonges T.G.N., Boon T.A., and van Moorselaar R.J.A. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 44 (2003) 51-56
17. Zaak D., Frimberger D., Stepp H., et al. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol 166 (2001) 1665-1668
18. Denzinger S., Burger M., Walter B., et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69 (2007) 675-679
19. Daniltchenko D.I., Riedl C.R., Sachs M.D., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174 (2005) 2129-2133
20. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52 (2007) 142-147